Pharmaceutical price regulation scheme 2014
A 5-year voluntary scheme on the control of prices agreed between government and the Association of the British Pharmaceutical Industry (ABPI).
Documents
Details
This document explains how the 2014 Pharmaceutical Price Regulation Scheme (PPRS) will provide assurance on the control of prices for the branded medicines bill for the NHS.
The scheme includes amendments by the ABPI and Department of Health to clarify the way in which spending under the Cancer Drugs Fund is treated by the scheme.
This document explains:
- status and membership of the scheme
- flexible pricing and patient access schemes
- PPRS payment mechanism
- levels of return and allowances
- dispute resolution
The 2014 PPRS is now superseded by the 2019 voluntary scheme for branded medicines pricing and access.
Updates to this page
Published 3 December 2013Last updated 22 January 2018 + show all updates
-
Responsibility for administering Patient Access Schemes (PAS) now sits with NHS England instead of DHSC. Wording in chapter 5 updated to reflect this change.
-
Updated the addendum to the 2014 pharmaceutical price regulation scheme to clarify the way in which spending under the Cancer Drugs Fund is treated by the scheme.
-
Added document: Addendum to the 2014 pharmaceutical price regulation scheme and explanatory text.
-
First published.